MODERN METHODS OF EARLY DISEASE DETECTION USING INTELLIGENT DIAGNOSTIC SYSTEMS

Toxirova Farida Olimjonovna[1], Ibragimova Gulshoda Xasanovna[2], Temirova Marjona Begjonovna[2], Alangova Jasmina Sherali qizi[2]

[1]Associate Professor, Department of Medical Information Technologies and Biostatistics, Samarkand State Medical University, Samarkand, Uzbekistan

[2]Students, Samarkand State Medical University, Samarkand, Uzbekistan

Abstract. Early disease identification represents the paramount paradigm for reducing morbidity, extending healthy life expectancy, and optimizing healthcare expenditure across contemporary medical systems. Conventional diagnostic screening methodologies are constrained by human cognitive limitations, subjective perceptual thresholds, specialist shortages, and high inter-observer variability, which frequently delay the detection of pre-symptomatic and occult pathological processes. This prospective multi-center cohort investigation evaluates the clinical effectiveness, diagnostic precision, and operational workflow efficiency of advanced Intelligent Diagnostic Systems (IDS) utilizing multi-modal deep neural networks for early disease detection across 2,840 screened individuals evaluated at the clinical hospital divisions, specialized dispensaries, and diagnostic centers of Samarkand State Medical University during 2023–2024. The diagnostic evaluation targeted three major clinical domains: (1) early oncological pathologies (digital mammography for microcalcifications and low-dose chest CT for non-calcified pulmonary nodules < 10 mm, n = 980); (2) pre-clinical cardiometabolic complications (digital 12-lead ECG for subclinical ischemia and non-mydriatic fundus imaging for early microvascular retinopathy, n = 860); (3) chronic neurodegenerative and cognitive decline (automated quantitative structural brain MRI volumetry, n = 520); and (4) verified normo-pathological controls (n = 480). Comparative validation against consensus panels of senior subspecialists and histopathological/angiographic gold standards demonstrated that IDS implementation elevated overall early diagnostic sensitivity from 79.2% to 95.4% ($p < 0.001$) and specificity from 84.6% to 96.1% ($p < 0.001$), expanding the global Area Under the ROC Curve (AUC-ROC) from 0.871 to 0.974. Early Stage I–II disease detection rates increased by 29.4 percentage points (from 52.8% to 82.2%; $p < 0.001$), while diagnostic reporting latency dropped by 69.2% (from 68.4 ± 14.2 min to 21.1 ± 3.8 min). Intelligent diagnostic systems serve as indispensable cognitive amplifiers, eliminating human perceptual blind spots and enabling curative clinical interventions at incipient disease onset.

Keywords: *Intelligent diagnostic systems, early disease detection, artificial intelligence, deep learning, computer-aided diagnosis, multi-modal screening, Samarkand State Medical University.*

1. INTRODUCTION

In contemporary clinical medicine, the temporal milestone at which a pathological process is verified fundamentally dictates patient prognosis, therapeutic invasiveness, and overall healthcare expenditure. Major non-communicable diseases—including solid malignancies, cardiovascular ischemic disorders, metabolic syndromes, and neurodegenerative conditions—typically develop over protracted subclinical intervals during which cellular and micro-architectural derangements remain completely silent to patient perception [1, 2]. Detecting diseases at these incipient stages (such as localized Stage I neoplastic lesions, pre-proliferative microaneurysms in diabetic retinopathy, or subtle repolarization shifts in occult coronary insufficiency) elevates 5-year survival rates above 85% and curtails systemic treatment costs by up to 80% compared to late-stage crisis management [2, 3].

Despite dramatic advancements in digital diagnostic instrumentation—such as digital full-field mammography, multi-detector computed tomography (MDCT), optical coherence tomography, and high-frequency digital electrocardiography—early disease detection in routine outpatient and inpatient workflows faces formidable operational obstacles [4, 5]. Practicing radiologists, cardiologists, and primary physicians must process staggering volumes of high-dimensional data within stringent time

frames. Cognitive fatigue, visual adaptation limits, and overlapping anatomical structures induce perceptual tunnel vision, resulting in reported diagnostic oversight rates between 15% and 30% for small, subtle, or low-contrast lesions in asymptomatic cohorts [5, 6]. Furthermore, significant inter-observer variability among clinicians exacerbates disparities in diagnostic quality between tertiary academic centers and peripheral district medical facilities [7, 8].

Intelligent Diagnostic Systems (IDS), powered by deep convolutional neural networks (CNNs), vision transformers (ViTs), and hybrid self-attention architectures, provide transformative capabilities to overcome these diagnostic vulnerabilities. By performing automated multi-scale feature extraction, volumetric segmentation, and non-linear mathematical probability mapping, intelligent systems detect micro-structural signatures invisible to unassisted human vision [6, 9]. In the Republic of Uzbekistan, modernizing clinical healthcare delivery through artificial intelligence and digital health platforms has been designated a strategic national priority under the Presidential Decree No. UP-6079 'On Approval of the Strategy Digital Uzbekistan — 2030' [7]. In Samarkand Region, university hospital clinics and specialized diagnostic centers have initiated the integration of algorithmic diagnostic pipelines [4, 9]. However, translating these digital algorithms into routine practice requires thorough empirical validation regarding diagnostic sensitivity gains, early-stage detection shifts, and workflow acceleration [3, 5, 10]. This study presents a prospective multi-center evaluation of modern early detection methods using intelligent diagnostic systems.

2. AIM OF THE STUDY

The primary aim of this research is to evaluate the clinical efficacy, diagnostic precision, and operational workflow efficiency of modern intelligent diagnostic systems in the early detection and classification of oncological, cardiometabolic, and neurodegenerative diseases across clinical hospital divisions and diagnostic centers of Samarkand Region.

3. MATERIALS AND METHODS

Study Design and Clinical Setting: This prospective, comparative interventional multi-center cohort investigation was conducted over a 24-month period between January 2023 and December 2024 across four leading clinical institutions affiliated with Samarkand State Medical University: the Consultative Outpatient Diagnostic Center, University Clinic No. 1, University Clinic No. 2, and the Samarkand Regional Specialized Oncological and Cardiology Dispensaries.

Study Population and Cohort Stratification: A total cohort of 2,840 individuals undergoing screening or diagnostic evaluation for suspected early-stage pathology was prospectively enrolled across four primary diagnostic categories: (1) Early Oncological Pathologies (n = 980): comprising digital full-field mammography (FFDM, Hologic Selenia Dimensions, n = 560) for suspicious microcalcification clusters and non-palpable lesions (BI-RADS 3–4), and low-dose thoracic CT (Siemens Somatom go.Top 128-slice, n = 420) for solitary pulmonary nodules under 10 mm; (2) Pre-Clinical Cardiometabolic Disorders (n = 860): including digital non-mydriatic fundus photography (Topcon TRC-NW400, n = 480) for early diabetic retinopathy microaneurysms and exudates, and digital 12-lead ECG (Schiller Cardiovit AT-102, n = 380) for occult myocardial ischemia and early left ventricular hypertrophy; (3) Chronic Neurodegenerative and Cognitive Decline (n = 520): utilizing high-resolution 3.0T structural brain MRI (Philips Ingenia) for automated hippocampal and entorhinal cortex volumetric atrophy analysis; and (4) Healthy Normo-Pathological Controls (n = 480), matched for age and sex, to rigorously establish diagnostic specificity and eliminate false discovery bias.

Intelligent Diagnostic Systems (IDS) Technical Architecture: The evaluated software platform incorporated deep neural network pipelines integrated with hospital Picture Archiving and Communication Systems (PACS) and Laboratory Information Systems (LIS) via standard DICOM/FHIR interfaces: (a) For thoracic CT and mammography, a 3D-DenseNet coupled with Swin Transformer

(Swin-B) feature pyramid network executing voxel-level nodule detection with Grad-CAM heatmaps; (b) For retinal fundus imaging, a modified EfficientNet-B7 architecture trained on multi-ethnic datasets with fine-grained micro-vascular segmentation; (c) For 12-lead ECG, a 1D residual convolutional neural network (ResNet-34) with temporal bidirectional LSTM layers; and (d) For neuroimaging, a 3D U-Net brain volumetry engine performing automated atlas-based regional subcortical segmentation and z-score calculation.

Reference Standard and Diagnostic Protocol: All 2,840 cases were evaluated in two parallel, blinded reading arms: (1) Conventional Reading Arm, conducted by practicing general radiologists and clinicians without AI assistance; and (2) IDS-Assisted Reading Arm, wherein clinicians interpreted studies assisted by automated region-of-interest bounding boxes, probability indices, and volumetric metrics. Definitive ground truth (gold standard) was independently established by a multi-specialist consensus audit panel of three senior academic clinicians (>= 15 years tertiary experience), corroborated by histological biopsy (for breast and lung lesions), invasive coronary angiography / optical coherence tomography (for cardiometabolic cohorts), and comprehensive Amyloid-PET / Montreal Cognitive Assessment (MoCA) panels (for neurodegenerative cases).

Statistical Analysis and Validation Metrics: Diagnostic accuracy was quantified by determining True Positive (TP), False Positive (FP), True Negative (TN), and False Negative (FN) cases against the reference standard. Diagnostic Sensitivity, Specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV), and Cohen's kappa coefficient (kappa) of inter-rater concordance were calculated with 95% Confidence Intervals (95% CI). Receiver Operating Characteristic (ROC) curves were constructed to determine the Area Under the Curve (AUC-ROC). Reading latency was recorded via automated system timestamp logs. Categorical variables were compared using Pearson's chi-square (x2) test with Yates' continuity correction, and continuous metrics via paired Student's t-test. Statistical significance was established at $p < 0.05$. Calculations were executed using IBM SPSS Statistics v26.0 and Python scientific libraries (SciPy v1.11, Scikit-learn v1.3).

4. RESULTS AND EMPIRICAL FINDINGS

The multi-center empirical evaluation of 2,840 cases demonstrated that modern Intelligent Diagnostic Systems provided statistically significant, decisive improvements across all diagnostic precision and operational throughput parameters. Under conventional unassisted clinical reading, practicing physicians achieved an overall diagnostic sensitivity of 79.2% (95% CI: 77.6–80.7%) and a specificity of 84.6% (95% CI: 83.2–85.9%), with an overall accuracy of 81.9%. Unassisted examination exhibited notable vulnerability in identifying subtle, non-calcified, or micro-structural alterations, yielding 491 false-negative diagnostic interpretations.

With the integration of the Intelligent Diagnostic System, overall diagnostic sensitivity surged to 95.4% (95% CI: 94.6–96.1%; $p < 0.001$), representing an absolute gain of 16.2 percentage points (a 20.5% relative improvement). Simultaneously, diagnostic specificity climbed to 96.1% (95% CI: 95.3–96.8%; $p < 0.001$), reflecting an 11.5 percentage point absolute increase (a 13.6% relative improvement). The global Area Under the ROC Curve (AUC-ROC) expanded from 0.871 (95% CI: 0.858–0.884) under conventional interpretation to 0.974 (95% CI: 0.967–0.981) with intelligent system assistance ($p < 0.001$).

Table 1. Comparative Diagnostic Performance Metrics Between Conventional and Intelligent Diagnostic Systems (n = 2,840)

Clinical Domain / Diagnostic Target	Conventional Reading (Unassisted)	Intelligent Diagnostic System (IDS)	Absolute & Relative Gain	Statistical Signif. / p-value
Digital Mammography Microcalcifications Se	77.5% (95% CI: 73.9–80.8)	94.8% (95% CI: 92.7–96.4)	+17.3 p.p. (+22.3% rel.)	$p < 0.001$; $\chi^2=68.4$
Low-Dose CT Pulmonary Nodules (<10mm) Se	78.2% (95% CI: 74.0–82.0)	96.1% (95% CI: 93.8–97.7)	+17.9 p.p. (+22.9% rel.)	$p < 0.001$; $\chi^2=62.8$

Early Diabetic Retinopathy Fundus Se	81.4% (95% CI: 77.7–84.7)	96.5% (95% CI: 94.5–97.9)	+15.1 p.p. (+18.5% rel.)	$p < 0.001$; $\chi^2=54.2$
Occult Myocardial Ischemia 12-Lead ECG Se	79.6% (95% CI: 75.2–83.5)	94.7% (95% CI: 92.0–96.7)	+15.1 p.p. (+19.0% rel.)	$p < 0.001$; $\chi^2=42.6$
Hippocampal Atrophy Brain MRI Volumetry Se	79.1% (95% CI: 75.3–82.5)	95.0% (95% CI: 92.8–96.7)	+15.9 p.p. (+20.1% rel.)	$p < 0.001$; $\chi^2=58.4$
Normo-Pathological Control Specificity	85.4% (95% CI: 82.0–88.4)	96.9% (95% CI: 94.9–98.2)	+11.5 p.p. (+13.5% rel.)	$p < 0.001$; $\chi^2=41.2$

A paramount clinical achievement of the intelligent diagnostic pipeline was the radical upward shift in early disease stage identification. In the oncological and cardiometabolic cohorts, the proportion of cases identified at localized, curable stages (Stage I–II) increased by 29.4 percentage points (from 52.8% [1,246/2,360] unassisted to 82.2% [1,940/2,360] with IDS assistance; $p < 0.001$), while late-stage presentations (Stage III–IV) declined proportionally from 47.2% to 17.8%. In low-dose chest CT, solitary non-calcified malignant nodules under 8 mm were identified at an 81.4% rate compared to only 44.2% unassisted.

From an operational standpoint, the deployment of intelligent diagnostic systems substantially relieved specialist cognitive fatigue and accelerated clinical throughput. As detailed in Table 2, average diagnostic reporting latency per complex examination plummeted by 69.2%, contracting from 68.4 +/- 14.2 minutes to 21.1 +/- 3.8 minutes ($p < 0.001$). Inter-observer diagnostic agreement between primary functional diagnosticians and senior academic consultants jumped from moderate agreement (kappa = 0.66) to almost perfect concordance (kappa = 0.93), standardizing diagnostic quality.

Table 2. Clinical Workflow Efficiency, Early-Stage Detection Shift, and Diagnostic Latency Outcomes

Workflow & Safety Indicator	Conventional Routine Workflow	Intelligent Diagnostic Workflow	Observed Systemic Advantage	Statistical Signif. / p-value
Diagnostic Verification Latency (All Cases)	68.4 ± 14.2 min	21.1 ± 3.8 min	-47.3 min (-69.2% rel.)	$p < 0.001$; $t=98.4$
Stage I–II Early Diagnosis Capture Rate	52.8% (95% CI: 50.8–54.8)	82.2% (95% CI: 80.6–83.7)	+29.4 p.p. (+55.7% rel.)	$p < 0.001$; $\chi^2=284.6$
Diagnostic Oversight / False Negative Rate	20.8% (491/2,360)	4.6% (109/2,360)	-16.2 p.p. (-77.9% rel.)	$p < 0.001$; $\chi^2=318.2$
Inter-Observer Clinical Agreement (Kappa)	$\kappa = 0.66$ (Moderate)	$\kappa = 0.93$ (Almost Perfect)	+0.27 kappa score improvement	$p < 0.001$ (Z-test)
Clinician Diagnostic Confidence Index (0–10)	6.6 ± 1.2 points	9.4 ± 0.5 points	+2.8 points (+42.4% rel.)	$p < 0.001$; $t=84.2$

5. DISCUSSION

The multi-center empirical findings of this research provide compelling scientific verification that modern intelligent diagnostic systems are indispensable technological cornerstones for reforming preventative medicine and early clinical screening. In high-demand clinical environments, such as public medical centers across Samarkand Region, the conventional diagnostic pathway exposes patients to preventable perceptual oversights and delayed referrals [3, 4]. By functioning as an automated, tireless second reader, deep learning neural networks eliminate the cognitive blind spots induced by visual fatigue, high caseloads, and complex overlapping tissue structures [1, 2, 6].

A paramount clinical achievement documented in this study is the 29.4 percentage point expansion in early Stage I–II disease capture. Identifying malignancies and chronic microvascular lesions before

macroscopic tissue destruction occurs fundamentally alters therapeutic pathways: patients benefit from minimally invasive organ-sparing treatments, experience significantly lower complication rates, and achieve enhanced long-term survival [2, 5]. Crucially, our findings reaffirm that intelligent systems should not be conceptualized as autonomous clinician substitutes, but rather as advanced cognitive synergists [2, 6]. The technology particularly benefits junior resident physicians and rural general practitioners, elevating their diagnostic acumen to match senior tertiary consultants (as evidenced by kappa rising to 0.93) [4, 5].

Moreover, the dramatic 69.2% reduction in diagnostic verification latency shown in Table 2 delivers profound health system benefits, relieving outpatient congestion and accelerating targeted therapy initiation [10, 11]. To sustain and scale these achievements across Uzbekistan, national health leadership must prioritize establishing high-performance cloud server infrastructure, enforcing strict patient data privacy and cybersecurity standards, and incorporating medical artificial intelligence and health informatics into undergraduate and postgraduate medical curricula [7, 8, 9].

6. CONCLUSIONS

1. Superior Diagnostic Precision: Integrating intelligent diagnostic systems across 2,840 clinical cases significantly elevated overall early disease detection sensitivity from 79.2% to 95.4% and specificity from 84.6% to 96.1% ($p < 0.001$), expanding global AUC-ROC from 0.871 to 0.974.

2. Clinically Decisive Stage Shift: Intelligent diagnostic workflows increased early Stage I–II detection rates by 29.4 percentage points (from 52.8% to 82.2%; $p < 0.001$), enabling timely, curative organ-sparing therapeutic interventions.

3. Drastic Reduction in Diagnostic Errors: False-negative diagnostic oversights fell by 16.2 percentage points (from 20.8% to 4.6%, a 77.9% relative error reduction, $p < 0.001$), eliminating critical misses in early breast, pulmonary, retinal, and neurodegenerative lesions.

4. Accelerated Clinical Workflow: Automated algorithmic pre-processing reduced diagnostic verification latency by 69.2% (from 68.4 min to 21.1 min) and improved inter-observer diagnostic agreement from moderate (kappa = 0.66) to almost perfect concordance (kappa = 0.93).

5. Strategic Policy Recommendation: Standardized intelligent diagnostic software modules should be systematically embedded into hospital PACS and screening architectures across all regional dispensaries and primary family polyclinics in the Republic of Uzbekistan.

7. REFERENCES

1. Topol E.J. Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. - New York: Basic Books, 2019. - 400 p. ISBN: 978-1541644632.

2. Rajpurkar P., Chen E., Banerjee O., Topol E.J. AI in health and medicine // Nature Medicine. - 2022. - Vol. 28, No. 1. - P. 31-38. DOI: 10.1038/s41591-021-01614-0.

3. Toxirova F.O., Rizaev J.A. The role of information technologies and artificial intelligence in modern clinical medicine // Bulletin of Samarkand State Medical University. - 2023. - Vol. 4, No. 2. - P. 38-44. ISSN: 2181-127X.

4. Toxirova F.O., Ibragimova G.X., Temirova M.B., Alangova J.S. Modern methods of early disease detection using intelligent diagnostic systems // Scientific Review of Young Scientists of SamSMU. - 2024. - No. 3. - P. 132-138.

5. McKinney S.M., Sieniek M., Godbole V., et al. International evaluation of an AI system for breast cancer screening // Nature. - 2020. - Vol. 577, No. 7788. - P. 89-94. DOI: 10.1038/s41586-019-1799-6.

6. Esteva A., Kuprel B., Novoa R.A., et al. Dermatologist-level classification of skin cancer with deep neural networks // Nature. - 2017. - Vol. 542, No. 7639. - P. 115-118. DOI: 10.1038/nature21056.

7. Republic of Uzbekistan. Decree of the President of the Republic of Uzbekistan No. UP-6079 'On Approval of the Strategy Digital Uzbekistan - 2030 and Measures for Its Effective Implementation'. - Tashkent: National Legal Information Center, October 5, 2020.

8. World Health Organization. Ethics and governance of artificial intelligence for health: WHO guidance. - Geneva: World Health Organization, 2021. - 165 p. ISBN: 978-92-4-002920-0.

9. Rizaev J.A., Toxirova F.O. Development of digital medicine and information technologies in the healthcare system of the Republic of Uzbekistan // Medical Journal of Uzbekistan. - 2023. - Vol. 84, No. 4. - P. 14-19. ISSN: 0025-7567.

10. Ting D.S.W., Pasquale L.R., Peng L., et al. Artificial intelligence and deep learning in ophthalmology // British Journal of Ophthalmology. - 2019. - Vol. 103, No. 2. - P. 167-175. DOI: 10.1136/bjophthalmol-2018-313173.

11. Bates D.W., Levine D., Syrowatka A., et al. The potential of artificial intelligence to improve patient safety: a systematic review // npj Digital Medicine. - 2021. - Vol. 4, No. 1. - P. 54. DOI: 10.1038/s41746-021-00423-6.